• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
  • Newsroom
    • Scientific Publications
    • Press Releases
    • Events
  • Partnering
  • Investors
    • Overview
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us

SITC 2023: Proof-of-concept of a non-gene editing technology using shRNA down-regulation to engineer allogeneic CAR T-cells

November 3, 2023

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Newsroom
  • Partnering
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2026 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use